Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB

Overview
Date Founded

1990

Headquarters

Vallongatan 1,Uppsala 752 28

Type of Company

Public

Employees (Worldwide)

63

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Contact Data
Trying to get in touch with decision makers at Oasmia Pharmaceutical AB? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Business Officer

Acting Chief Medical Officer

Chief Technical Officer

GM Europe & Russia

Head of Regulatory Affairs

Head of Research & Development

Strategic Marketing Director

Board of Directors

Former President & Chief Executive Officer at ADAMA Agricultural Solutions Ltd.

Director at Wingfirm Pharma AB

Chief Executive Officer at Granen Fastighetsutveckling AB

Deputy Director at Comtax AB

Paths to Oasmia Pharmaceutical AB
Potential Connections via
Relationship Science
You
Oasmia Pharmaceutical AB
Recent Transactions
Details Hidden

Oasmia Pharmaceutical AB purchases Karo Pharma AB /Clinical Cancer Project from Karo Pharma AB

Details Hidden

Oasmia Pharmaceutical AB issued USD American Depositary Shares (ADS)

Details Hidden

Oasmia Pharmaceutical AB issued EUR Ordinary Shares

Transaction Advisors
Auditor

Advised onOasmia Pharmaceutical AB issued USD American Depositary Shares (ADS)

Underwriter

Advised onOasmia Pharmaceutical AB issued USD American Depositary Shares (ADS)

Underwriter

Advised onOasmia Pharmaceutical AB issued USD American Depositary Shares (ADS)

Advisors & Consultants
Auditor

Professional at PricewaterhouseCoopers LLP

Auditor

Professional at KPMG LLP

Publicist

Director, Communications at del Sol Foundation for Energy Security

Clients

HLB Co., Ltd. engages in the manufacture and sale of composite materials. Its products include lifeboats using fiber-reinforced plastic and pipes for ballast, cooling water lines, industrial water, sea water piping, and others. The company was founded on October 18, 1985 and is headquartered in Ulsan, South Korea.

Medison Pharma Ltd. markets and distributes medical, pharmaceutical, and diagnostics devices and products. It offers services like registration, reimbursement, nursing, distribution, and marketing. The firm is a marketing group, which represents niche healthcare products from companies such as Biogen Idec, Amgen, Shire and Ipsen. The company was founded by Meir Jakobsohn in 1996 and is headquartered in Petach Tikva, Israel.

Hetero Drugs Ltd. manufactures and markets pharmaceutical ingredients. It manufactures and markets Active Pharmaceutical Ingredients (APIs), intermediate, and finished dosages. The company was founded by Bandi Partha Saradhi Reddy in 1993 and is headquartered in Hyderabad, India.

Key Stats and Financials As of 2020
Market Capitalization
$217M
Total Enterprise Value
$272M
Earnings Per Share
$0
Three Year Compounded Annual Growth Rate Of Revenue
954.76%
EBITDAMargin
-6.87%
Enterprise Value / Sales
13.14x
TEVNet Income
-251.88x
Debt TEV
0.04x
Revenue
$20.7M
Total Debt
$9.64M
Total Equity
$83.9M
EBITDA
$-1.42M
Net Profit
$-1.08M
Suppliers
Baxter International, Inc. Pharmaceuticals | Deerfield, IL

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Oasmia Pharmaceutical AB. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Oasmia Pharmaceutical AB's profile does not indicate a business or promotional relationship of any kind between RelSci and Oasmia Pharmaceutical AB.